168 related articles for article (PubMed ID: 38148378)
1. Evaluation of the ovicidal activity and fasciolicidal activity of the extract of ethyl acetate from Artemisia ludoviciana Nutt. spp. mexicana and of artemisinin against adult parasites of Fasciola hepatica.
Ezeta-Miranda A; Avila-Acevedo JG; Vera-Montenegro Y; Francisco-Marquez G
Parasitol Res; 2023 Dec; 123(1):71. PubMed ID: 38148378
[TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of albendazole and triclabendazole ovicidal activity on Fasciola hepatica eggs.
Alvarez L; Moreno G; Moreno L; Ceballos L; Shaw L; Fairweather I; Lanusse C
Vet Parasitol; 2009 Oct; 164(2-4):211-6. PubMed ID: 19560276
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of purified fractions of Artemisia ludoviciana Nutt. mexicana and ultraestructural damage to newly excysted juveniles of Fasciola hepatica in vitro.
Ezeta-Miranda A; Vera-Montenegro Y; Avila-Acevedo JG; García-Bores AM; Estrella-Parra EA; Francisco-Marquez G; Ibarra-Velarde F
Vet Parasitol; 2020 Sep; 285():109184. PubMed ID: 32835931
[TBL] [Abstract][Full Text] [Related]
4. Fasciola hepatica: histological changes in the reproductive structures of triclabendazole (TCBZ)-sensitive and TCBZ-resistant flukes after treatment in vivo with TCBZ and the related benzimidazole derivative, Compound Alpha.
Hanna RE; Edgar HW; McConnell S; Toner E; McConville M; Brennan GP; Devine C; Flanagan A; Halferty L; Meaney M; Shaw L; Moffett D; McCoy M; Fairweather I
Vet Parasitol; 2010 Mar; 168(3-4):240-54. PubMed ID: 20053501
[TBL] [Abstract][Full Text] [Related]
5. Resistance of Fasciola hepatica against Triclabendazole in cattle in Cajamarca (Peru): a clinical trial and an in vivo efficacy test in sheep.
Ortiz P; Scarcella S; Cerna C; Rosales C; Cabrera M; Guzmán M; Lamenza P; Solana H
Vet Parasitol; 2013 Jul; 195(1-2):118-21. PubMed ID: 23352107
[TBL] [Abstract][Full Text] [Related]
6. Fasciola hepatica: a comparative survey of adult fluke resistance to triclabendazole, nitroxynil and closantel on selected upland and lowland sheep farms in Northern Ireland using faecal egg counting, coproantigen ELISA testing and fluke histology.
Hanna RE; McMahon C; Ellison S; Edgar HW; Kajugu PE; Gordon A; Irwin D; Barley JP; Malone FE; Brennan GP; Fairweather I
Vet Parasitol; 2015 Jan; 207(1-2):34-43. PubMed ID: 25529143
[TBL] [Abstract][Full Text] [Related]
7. Understanding the main route of drug entry in adult Fasciola hepatica: Further insights into closantel pharmacological activity.
Ceballos L; Canton C; Cadenazzi G; Larsen K; Virkel G; Moreno L; Fairweather I; Lanusse C; Alvarez L
Exp Parasitol; 2017 Oct; 181():23-29. PubMed ID: 28734749
[TBL] [Abstract][Full Text] [Related]
8. Disruption of vitellogenesis and spermatogenesis by triclabendazole (TCBZ) in a TCBZ-resistant isolate of Fasciola hepatica following incubation in vitro with a P-glycoprotein inhibitor.
Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
Parasitology; 2014 Jul; 141(8):1064-79. PubMed ID: 24889697
[TBL] [Abstract][Full Text] [Related]
9. Standardisation of a coproantigen reduction test (CRT) protocol for the diagnosis of resistance to triclabendazole in Fasciola hepatica.
Flanagan AM; Edgar HW; Forster F; Gordon A; Hanna RE; McCoy M; Brennan GP; Fairweather I
Vet Parasitol; 2011 Feb; 176(1):34-42. PubMed ID: 21093156
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica.
McConville M; Brennan GP; Flanagan A; Edgar HW; Hanna RE; McCoy M; Gordon AW; Castillo R; Hernández-Campos A; Fairweather I
Vet Parasitol; 2009 May; 162(1-2):75-88. PubMed ID: 19282108
[TBL] [Abstract][Full Text] [Related]
11. In vitro effects of triclabendazole (TCBZ) on the excretory-secretory products (ESP) of Fasciola spp parasites.
Farahnak A; Golmohamdi T; Eshraghian M
Acta Med Iran; 2012; 50(3):164-8. PubMed ID: 22418984
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78.
Duthaler U; Smith TA; Keiser J
Antimicrob Agents Chemother; 2010 Nov; 54(11):4596-604. PubMed ID: 20733042
[TBL] [Abstract][Full Text] [Related]
13. Assessment of flukicide efficacy against Fasciola hepatica in sheep in Sweden in the absence of a standardised test.
Novobilský A; Amaya Solis N; Skarin M; Höglund J
Int J Parasitol Drugs Drug Resist; 2016 Dec; 6(3):141-147. PubMed ID: 27380550
[TBL] [Abstract][Full Text] [Related]
14. Current Threat of Triclabendazole Resistance in Fasciola hepatica.
Kelley JM; Elliott TP; Beddoe T; Anderson G; Skuce P; Spithill TW
Trends Parasitol; 2016 Jun; 32(6):458-469. PubMed ID: 27049013
[TBL] [Abstract][Full Text] [Related]
15. Resistance of Fasciola hepatica against triclabendazole in cattle in Patagonia (Argentina).
Olaechea F; Lovera V; Larroza M; Raffo F; Cabrera R
Vet Parasitol; 2011 Jun; 178(3-4):364-6. PubMed ID: 21277090
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.
Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
Parasitol Res; 2011 Oct; 109(4):981-95. PubMed ID: 21442257
[TBL] [Abstract][Full Text] [Related]
17. Increased action of triclabendazole (TCBZ) in vitro against a TCBZ-resistant isolate of Fasciola hepatica following its co-incubation with the P-glycoprotein inhibitor, R(+)-verapamil.
Savage J; Meaney M; Brennan GP; Hoey E; Trudgett A; Fairweather I
Exp Parasitol; 2013 Nov; 135(3):642-53. PubMed ID: 24090567
[TBL] [Abstract][Full Text] [Related]
18. The T687G SNP in a P-glycoprotein gene of Fasciola hepatica is not associated with resistance to triclabendazole in two resistant Australian populations.
Elliott TP; Spithill TW
Mol Biochem Parasitol; 2014 Nov; 198(1):45-7. PubMed ID: 25481750
[TBL] [Abstract][Full Text] [Related]
19. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes.
Alvarez LI; Solana HD; Mottier ML; Virkel GL; Fairweather I; Lanusse CE
Parasitology; 2005 Oct; 131(Pt 4):501-10. PubMed ID: 16174415
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole.
Devine C; Brennan GP; Lanusse CE; Alvarez LI; Trudgett A; Hoey E; Fairweather I
Vet Parasitol; 2012 Feb; 184(1):37-47. PubMed ID: 21872399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
